Voyager Therapeutics Inc. (VYGR) Trading Up 5.9%
Shares of Voyager Therapeutics Inc. (NASDAQ:VYGR) were up 5.9% during mid-day trading on Friday . The company traded as high as $13.92 and last traded at $13.41, with a volume of 54,282 shares changing hands. The stock had previously closed at $12.66.
A number of analysts have recently issued reports on VYGR shares. Stifel Nicolaus started coverage on Voyager Therapeutics in a research report on Thursday, July 14th. They set a “buy” rating and a $33.00 price target for the company. Wells Fargo & Co. started coverage on Voyager Therapeutics in a research report on Friday, May 20th. They set an “outperform” rating for the company. Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 7th. Cowen and Company reiterated a “buy” rating on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Finally, Piper Jaffray Cos. reiterated a “buy” rating on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $30.25.
The stock’s market capitalization is $370.74 million. The firm has a 50 day moving average price of $12.71 and a 200-day moving average price of $11.76.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Thursday, May 12th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.67. Analysts expect that Voyager Therapeutics Inc. will post ($1.46) earnings per share for the current fiscal year.
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.